◎ Sugi Atlas

Atlas / Drug / Satavaptan

Satavaptan

drug
On this page

Also known as AquildaSatavaptan monophosphateSatavaptan phosphateSR 121463SR 121463ASR 121463BSR-121463SR-121463ASR-121463BSr121463SR121463BSR121463F

Summary

Satavaptan (CHEMBL2107777) is a phase-3 clinical-stage small molecule targeting AVPR1A, AVPR1B, and AVPR2; indicated across 4 conditions including cirrhosis of liver and inappropriate adh syndrome.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Small molecule
  • Targets: 3 (AVPR1A, AVPR1B, AVPR2)
  • Indications: 4 conditions
  • Clinical trials: 11
  • Chemistry: 627.8 Da · C33H45N3O7S

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL2107777
NameSatavaptan
TypeSmall molecule
Max phase3
FDA approvedno
PubChem CID70693556
Molecular formulaC33H45N3O7S
Molecular weight627.8
InChIKeyCDSBFDCCJJDFCV-UHFFFAOYSA-N

SMILES: CCOC1=CC2=C(C=C1)N(C(=O)C23CCC(CC3)CCN4CCOCC4)S(=O)(=O)C5=C(C=C(C=C5)C(=O)NC(C)(C)C)OC

IUPAC name: N-tert-butyl-4-[5’-ethoxy-4-(2-morpholin-4-ylethyl)-2’-oxospiro[cyclohexane-1,3’-indole]-1’-yl]sulfonyl-3-methoxybenzamide

Also known as: Aquilda, Satavaptan, Satavaptan monophosphate, Satavaptan phosphate, SR 121463, SR 121463A, SR 121463B, SR-121463, SR-121463A, SR-121463B, Sr121463, SR121463B

Patent coverage: 77 distinct patent families (191 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
AVPR1AV1A receptorAntagonist6.54.6%P37288
AVPR1BV1B receptorAntagonist4.30.4%P47901
AVPR2V2 receptorAntagonist9.30%P30518

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 3 target gene(s): AVPR1A, AVPR1B, AVPR2.

Top Reactome pathways

8 total, by targets touching each:

PathwayTargetsGenes
Vasopressin-like receptors3AVPR1A, AVPR1B, AVPR2
G alpha (q) signalling events2AVPR1A, AVPR1B
Defective AVP does not bind AVPR1A,B and causes neurohypophyseal diabetes insipidus (NDI)2AVPR1A, AVPR1B
G alpha (s) signalling events1AVPR2
Vasopressin regulates renal water homeostasis via Aquaporins1AVPR2
Cargo recognition for clathrin-mediated endocytosis1AVPR2
Clathrin-mediated endocytosis1AVPR2
Defective AVP does not bind AVPR2 and causes neurohypophyseal diabetes insipidus (NDI)1AVPR2

Dominant GO biological processes

GO termTargets
regulation of systemic arterial blood pressure by vasopressin3
G protein-coupled receptor signaling pathway3
cellular response to hormone stimulus3
positive regulation of vasoconstriction3
signal transduction3
positive regulation of systemic arterial blood pressure2
positive regulation of cytosolic calcium ion concentration2
positive regulation of cell population proliferation2
telencephalon development2
transport across blood-brain barrier2
regulation of blood pressure2
positive regulation of blood pressure2
maternal aggressive behavior1
generation of precursor metabolites and energy1
negative regulation of female receptivity1

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
cirrhosis of liver3MONDO:0005155EFO:0001422
inappropriate ADH syndrome3MONDO:0006802EFO:1000982

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 11.

Phase distribution

PhaseTrials
PHASE37
PHASE24

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00264914PHASE3COMPLETEDSafety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion
NCT00264927PHASE3COMPLETEDEfficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion
NCT00274326PHASE3COMPLETEDDILIPO (DILutIonal HyPOnatremia)
NCT00358878PHASE3COMPLETEDCirrhotic Ascites Treatment With Satavaptan in Patients With Ascites Due to Cirrhosis of the Liver (CATS)
NCT00359437PHASE3TERMINATEDSatavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver
NCT00366795PHASE3TERMINATEDSatavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver
NCT00728091PHASE3TERMINATEDA Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia
NCT00032734PHASE2COMPLETEDEfficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion
NCT00501384PHASE2COMPLETEDSatavaptan Dose-Ranging Study in the Prevention of Ascites
NCT00501566PHASE2COMPLETEDSatavaptan Dose-Ranging Study in Normonatraemic Patients With Cirrhotic Ascites
NCT00501722PHASE2COMPLETEDSatavaptan Dose-Ranging Study in Hyponatraemic Patients With Cirrhotic Ascites

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

144 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
DESMOPRESSINChEMBL + PubChemPhase 4 (approved)AVPR1A, AVPR1B, AVPR2
OXYTOCINChEMBL + PubChemPhase 4 (approved)AVPR1A, AVPR1B, AVPR2
ATOSIBANChEMBLPhase 4 (approved)AVPR1A, AVPR1B, AVPR2
CARBETOCINChEMBLPhase 4 (approved)AVPR1A, AVPR1B, AVPR2
MOZAVAPTANChEMBLPhase 4 (approved)AVPR1A, AVPR1B, AVPR2
VASOPRESSINChEMBLPhase 4 (approved)AVPR1A, AVPR1B, AVPR2
NELIVAPTANChEMBLPhase 2AVPR1A, AVPR1B, AVPR2
ORNIPRESSINChEMBLPhase 2AVPR1A, AVPR1B, AVPR2
PECAVAPTANChEMBLPhase 2AVPR1A, AVPR1B, AVPR2
SELEPRESSINChEMBLPhase 2AVPR1A, AVPR1B, AVPR2
PIMOZIDEChEMBL + PubChemPhase 4 (approved)AVPR1A, AVPR2
RIFAMPINChEMBL + PubChemPhase 4 (approved)AVPR1A, AVPR2
TEGASERODChEMBL + PubChemPhase 4 (approved)AVPR1A, AVPR2
BALSALAZIDEChEMBLPhase 4 (approved)AVPR1A, AVPR2
BOSUTINIBChEMBLPhase 4 (approved)AVPR1A, AVPR2
CHLORHEXIDINEChEMBLPhase 4 (approved)AVPR1A, AVPR2
CONIVAPTANChEMBLPhase 4 (approved)AVPR1A, AVPR2
FLUSPIRILENEChEMBLPhase 4 (approved)AVPR1A, AVPR2
NITAZOXANIDEChEMBLPhase 4 (approved)AVPR1A, AVPR2
PYRVINIUMChEMBLPhase 4 (approved)AVPR1A, AVPR2
RIFAXIMINChEMBLPhase 4 (approved)AVPR1A, AVPR2
TOLVAPTANChEMBLPhase 4 (approved)AVPR1A, AVPR2
BALOVAPTANChEMBLPhase 3AVPR1A, AVPR2
LIXIVAPTANChEMBLPhase 3AVPR1A, AVPR2
OTILONIUM BROMIDEChEMBLPhase 3AVPR1A, AVPR2
BENZETHONIUMChEMBLPhase 2AVPR1A, AVPR2
DOMIPHENChEMBLPhase 2AVPR1A, AVPR2
RELCOVAPTANChEMBLPhase 2AVPR1A, AVPR2
AbirateronePubChemApprovedAVPR1A, AVPR2
acetylcysteinePubChemApprovedAVPR1A, AVPR2
Aclidinium BromidePubChemApprovedAVPR1A, AVPR2
AcyclovirPubChemApprovedAVPR1A, AVPR2
AfatinibPubChemApprovedAVPR1A, AVPR2
AllopurinolPubChemApprovedAVPR1A, AVPR2
AlmotriptanPubChemApprovedAVPR1A, AVPR2
AlogliptinPubChemApprovedAVPR1A, AVPR2
aminolevulinic acidPubChemApprovedAVPR1A, AVPR2
AnagrelidePubChemApprovedAVPR1A, AVPR2
ApixabanPubChemApprovedAVPR1A, AVPR2
AprepitantPubChemApprovedAVPR1A, AVPR2
BelzutifanPubChemApprovedAVPR1A, AVPR2
BosentanPubChemApprovedAVPR1A, AVPR2
ClofarabinePubChemApprovedAVPR1A, AVPR2
ClozapinePubChemApprovedAVPR1A, AVPR2
CrizotinibPubChemApprovedAVPR1A, AVPR2
DacarbazinePubChemApprovedAVPR1A, AVPR2
DesloratadinePubChemApprovedAVPR1A, AVPR2
Desoxycorticosterone PivalatePubChemApprovedAVPR1A, AVPR2
DidanosinePubChemApprovedAVPR1A, AVPR2
DihydroergotaminePubChemApprovedAVPR1A, AVPR2
ErythromycinPubChemApprovedAVPR1A, AVPR2
EthambutolPubChemApprovedAVPR1A, AVPR2
FidaxomicinPubChemApprovedAVPR1A, AVPR2
FulvestrantPubChemApprovedAVPR1A, AVPR2
GanciclovirPubChemApprovedAVPR1A, AVPR2
GefitinibPubChemApprovedAVPR1A, AVPR2
GlycopyrrolatePubChemApprovedAVPR1A, AVPR2
LeucovorinPubChemApprovedAVPR1A, AVPR2
LinagliptinPubChemApprovedAVPR1A, AVPR2
MethotrexatePubChemApprovedAVPR1A, AVPR2

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot